Knockdown of antizyme inhibitor decreases prostate tumor growth in vivo
The endogenous protein antizyme inhibitor (AZI) is a potential oncogene which promotes cell growth by both inhibiting antizyme (AZ) activity and releasing ornithine decarboxylase (ODC) from AZ-mediated degradation. High levels of ODC and polyamines are associated with numerous types of neoplastic tr...
Main Authors: | Olsen, R.R., Chung, I., Zetter, B.R. |
---|---|
Format: | Article |
Language: | English |
Published: |
2012
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/5081/1/Olsen-2012-Knockdown_of_antizym.pdf |
Similar Items
-
Antizyme inhibitor family: biological and translational research implications
by: Qiaohui Feng, et al.
Published: (2024-01-01) -
A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis.
by: Spivey, K.A., et al.
Published: (2012) -
Ornithine decarboxylase antizyme finder (OAF): Fast and reliable detection of antizymes with frameshifts in mRNAs
by: Atkins John F, et al.
Published: (2008-04-01) -
Alpha-tomatine attenuation of in vivo growth of subcutaneous and orthotopic xenograft tumors of human prostate carcinoma Pc-3 cells is accompanied by inactivation of nuclear factor-kappa b signaling
by: Lee, S.T., et al.
Published: (2013) -
Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells
by: Patel, Nish, et al.
Published: (2010)